BioScrip, Inc. (Nasdaq: BIOS) today announced that the Company will release its 2010 third quarter financial results before the market opens on Tuesday, November 2, 2010 and host a conference call shortly thereafter at 8:30 a.m. Eastern Time. Richard H. Friedman, Chairman and Chief Executive Officer, Richard M. Smith, President and Chief Operating Officer, and Stanley G. Rosenbaum, Executive Vice President and Chief Financial Officer, will host the call.

Interested parties may participate in the conference call by dialing 800-909-4195 (US), or 212-231-2905 (International), 5-10 minutes prior to the start of the call. A replay of the conference call will be available shortly after the call’s conclusion on Tuesday, November 2, through 10:30 a.m. Eastern Time on Wednesday, November 17, by dialing 800-633-8284 (US), or 402-977-9140 (International), and entering reservation #21485382. An audio web cast and archive of the conference call will also be available under the “Investor Relations” section of the BioScrip website at www.bioscrip.com.

About BioScrip, Inc.

BioScrip, Inc. (www.bioscrip.com) (Nasdaq: BIOS) is a national provider of specialty pharmacy and home care products and services that partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and delivery of cost-effective access to prescription medications. Our services are designed to improve clinical outcomes for chronic and acute healthcare conditions while controlling overall healthcare costs.

Forward Looking Statements-Safe Harbor

This press release may contain statements which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent, belief or current expectations of the Company, its directors, or its officers with respect to the future operating performance of the Company, Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Important factors that could cause such differences are described in the Company’s periodic filings with the Securities and Exchange Commission.

BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024 Plus de graphiques de la Bourse BioPlus Acquisition
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024 Plus de graphiques de la Bourse BioPlus Acquisition